2024-11-26 05:34:20
Innovent Receives NMPA Breakthrough Designation for IBI310, the Anti-CTLA-4 Monoclonal Antibody, Combined with Sintilimab in Advanced Cervical Cancer Treatment
Corporate/ 2023-07-24
Innovent Receives NMPA Breakthrough Desi...

SAN FRANCISCO and SUZHOU,China,April 14,2022--Innovent Biologics,Inc. ("Innovent") (HKEX: 01801),a world-class biopharmaceutical c...

First Patients Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent
Corporate/ 2023-07-24
First Patients Dosed with Illuccix® - T...

Physicians in Indiana,New York City,and Washington are among the first to administer Illuccix® – demonstrating coast-to-coast availabil...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release